Test Price
2,800 AED✅ Home Collection Available
FLCN Gene (Birt‑Hogg‑Dubé Syndrome) Genetic Test in UAE | 2,800 AED | DHA Licensed
Executive Summary & Core Metrics
- Diagnostic Accuracy: 99.9% analytical sensitivity via ISO 9001:2015 accredited next‑generation sequencing (NGS) pipeline.
- Specimen Logistics: VIP mobile phlebotomy and temperature‑controlled cold‑chain home collection available daily from 8 AM to 11 PM. For FTA card submissions, secure courier retrieval is provided.
- Clinical Oversight: Post‑test telephonic correlation and genetic counselling delivered by a DHA‑licensed Consultant Medical Geneticist.
- Insurance & Billing: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The FLCN gene test detects germline mutations associated with Birt‑Hogg‑Dubé (BHD) syndrome, a hereditary disorder that increases the lifetime risk of fibrofolliculomas, spontaneous pneumothorax, and renal cell carcinoma. This next‑generation sequencing (NGS) assay analyses the full coding region and flanking intronic boundaries from whole blood, extracted DNA, or a single dried blood spot on an FTA card. Results enable precise risk stratification, family cascade screening, and early surveillance recommendations aligned with current medical guidelines.
| Feature | Our NGS Test | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Analytical Sensitivity | 99.9% (complete gene coverage) | ~98% (only targeted exons) |
| Methodology | NGS with bioinformatics pipeline | Sanger sequencing of individual amplicons |
| Turnaround Time | 3–4 weeks | 4–6 weeks |
| Regulatory Accreditation | ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) + DHA Facility 1143 | Variable; often lacks UAE‑specific licensing |
Physician Insight & Safety Protocols
“Detection of a pathogenic FLCN variant is not a cancer diagnosis—it is an opportunity for proactive surveillance. The true clinical value emerges when results are interpreted alongside a three‑generation pedigree and followed by a personalised screening plan. I strongly advise every patient to review their report with a qualified clinical geneticist before drawing any conclusions about their health trajectory.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory Safety Protocols
- Medication Continuity: Do not alter or discontinue any prescribed therapy without consulting your treating physician prior to sample collection.
- Pre‑Test Counselling: A dedicated genetic counselling session to construct a detailed family pedigree is strongly recommended before specimen submission.
- Specimen Integrity: Whole blood samples must be transported via temperature‑controlled cold chain; FTA cards can be shipped at ambient temperature using the provided secure medical courier envelope.
- Post‑Test Follow‑Up: A telephonic consultation with our genetics team is included to ensure you understand your results and the recommended surveillance pathway.
Exclusion Criteria & Contraindications
- Acute Medical Emergencies: This test is not suitable for individuals experiencing sudden severe breathlessness, sharp unilateral chest pain, or new‑onset haemoptysis. Such symptoms require immediate emergency department evaluation.
- Rapidly Evolving Lesions: A quickly enlarging facial papule, nodule, or any skin lesion with bleeding should be assessed by a dermatologist or oncologist prior to genetic testing.
- Incomplete Clinical History: Testing may be deferred if an adequate family history or pedigree cannot be obtained, as the interpretation of variants of unknown significance relies on segregation data.
- Known Variant Carriers: Individuals who have already undergone targeted FLCN testing and carry a confirmed pathogenic variant do not require repeat sequencing unless indicated for clinical trial eligibility.
Patient FAQ & Clinical Guidance
1. What does a positive FLCN gene test mean for my cancer risk?
A positive result confirms a hereditary predisposition to Birt‑Hogg‑Dubé syndrome, which elevates the lifetime risk of renal cell carcinoma to approximately 15–30%. Immediate oncological screening and regular renal imaging (ultrasound or MRI) are recommended. It does not mean cancer is present—it signals the need for enhanced surveillance.
2. Can I use a simple finger‑prick blood drop for this test?
Yes, a single drop of blood dried on an FTA card is a fully validated specimen type. Our NGS protocol extracts high‑quality genomic DNA without venipuncture, making collection painless and stable at room temperature. A secure courier envelope is provided for return shipping.
3. How quickly will I receive my results, and who interprets them?
Results are reported within 3 to 4 weeks from sample receipt. A DHA‑licensed Consultant Medical Geneticist reviews the sequencing data and provides a telephonic post‑test correlation, ensuring you understand the clinical implications and recommended next steps for you and your family.
4. Is genetic counselling included in the test price?
Yes, a pre‑test counselling session to construct a family pedigree and a post‑test telephonic consultation are both included in the 2,800 AED fee. These consultations are conducted by our genetics team and are essential for accurate variant interpretation and risk communication.
5. What sample types are accepted, and how should I prepare?
Accepted specimens include whole blood (collected via venipuncture), extracted DNA, or a dried blood spot on an FTA card. No fasting or special preparation is required. For home collection, our VIP mobile phlebotomy team can visit between 8 AM and 11 PM daily.
UAE Regulatory & Data Privacy Adherence
Data Protection & Confidentiality: All genetic data is processed in full compliance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Your genetic information is encrypted, access‑controlled, and never shared with third parties without explicit written consent.
Clinical Safety & Consent: Sample collection and reporting follow the standards set out in Federal Decree‑Law No. 4 of 2016 on Medical Liability. Informed consent is obtained prior to testing, and all procedures are conducted under the supervision of DHA‑licensed healthcare professionals.
Facility Accreditation: Testing is performed at the DNA Labs UAE facility (DHA License: 1143) located at Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE. The laboratory operates under ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139).
Clinical & Logistical Metadata
| Test Name | FLCN Gene (Birt‑Hogg‑Dubé Syndrome) Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type / Matrix | Whole Blood, Extracted DNA, or FTA Card (Dried Blood Spot) |
| Methodology Used | Next‑Generation Sequencing (NGS) with Bioinformatics Pipeline |
| ICD-10-CM Code | Q89.8 |
| LOINC Code | 81304-3 |
| DHA Facility License & Laboratory Address | DHA License: 1143 | DNA Labs UAE, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians